Immix Biopharma, Inc. (ImmixBio™) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Their lead asset IMX-110 holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma and has received Rare Pediatric Disease Designation (RPDD) for the treatment of rhabdomyosarcoma, a life-threatening form of cancer in children. The company is also developing IMX-120, a biologic for inflammatory bowel disease (IBD), and anticipates filing an IND for IMX-120 in 2023.

Immix Biopharma (Nasdaq: IMMX)

Immix Biopharma, Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Immix Biopharma, Inc. Common Stock

Immix Biopharma, Inc. (ImmixBio™) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.

Mesa Verde Venture Partners

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Read the press release here: https://loom.ly/1Pu09G0

#cancertreatment #biopharma #sciencenews

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Read the press release here: https://loom.ly/4PQGN9c

#science #biopharma #cancertreatment #multiplemyeloma #car-t

Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Read the press release here: https://loom.ly/HCKoAzU

#cancertreatment #science #biopharma

Immix Biopharma is pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ 

Read more here: https://lnkd.in/emdDgvbQ

#science #cancertreatment #technology

Immix Biopharma's subsidiary Nexcella, Inc. 

Learn more about Nexcella, Inc.: https://nexcella.com/  

#biopharma #cancertreatment #science

Who founded Immix Biopharma?

Read more here: https://lnkd.in/enZ6FH3s 

#science #cancer #biopharma

Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference

#healthcare #science #biopharma

Dr. Suzanne Lentzsch Joins Immix Biopharma Scientific Advisory Board

Read the press release here: https://loom.ly/spWfYjU

#sciencenews #biopharma

FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for the following: 

Read the press release here: https://loom.ly/fwrLYNQ

#fda #science #cancer

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

Read the press release here: https://loom.ly/fwrLYNQ 

#science #biopharma #sciencenews

COM:IMMIXBIO

Immix Biopharma, Inc.

2.04

−3.32%

−0.05

Last Close

2.09

09/05 20:00

Market Cap

56.78M

Beta: -

Volume Today

276.22K

Avg: -

name

homepage url

country

linkedin url

crunchbase url

employee count

sector

industry

Description

peer of

investor of

Metrics